Scarica l'app Stockscreener
3.51
0.57%
0.02
Polypid Ltd Borsa (PYPD) Ultime notizie
Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating - MarketScreener
Roth Capital Adjusts PolyPid (PYPD) Price Target Amid New Financing | PYPD Stock News - GuruFocus
PolyPid (NASDAQ:PYPD) Given New $14.00 Price Target at JMP Securities - Defense World
PYPD: JMP Securities Lowers Price Target While Maintaining Marke - GuruFocus
PolyPid (PYPD) Price Target Adjusted Amid Financing Developments - GuruFocus
PolyPid stock price target lowered to $14 at JMP on warrant dilution By Investing.com - Investing.com South Africa
PolyPid stock price target lowered to $14 at JMP on warrant dilution - Investing.com Australia
PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial - TipRanks
Citizens JMP Adjusts Price Target for PolyPid (PYPD) Amid Warrant Developments | PYPD Stock News - GuruFocus
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire Inc.
FY2026 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World
PESG Research Update: PolyPid SHIELD’s II Delivers - GlobeNewswire
PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline ResultsParadigm Shift in Surgical Infection Prevention - Yahoo
In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed - insights.citeline.com
HC Wainwright Issues Positive Forecast for PolyPid (NASDAQ:PYPD) Stock Price - Defense World
PolyPid reports positive phase 3 surgical infection drug trial - גלובס
PolyPid (PYPD) Target Price Increased as Phase 3 Trial Data Impr - GuruFocus
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial - Benzinga
PolyPid shares surge on successful D-PLEX100 trial results By Investing.com - Investing.com South Africa
PolyPid shares surge on successful D-PLEX100 trial results - Investing.com Australia
Transcript : PolyPid Ltd.Special Call - MarketScreener
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - The Manila Times
PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial - marketscreener.com
PolyPid (PYPD) Reports Positive Phase 3 Trial Results for D-PLEX100 | PYPD Stock News - GuruFocus
PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial - TipRanks
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - GlobeNewswire
What is Roth Capital’s Forecast for PolyPid Q2 Earnings? - Defense World
Roth Capital Begins Coverage on PolyPid (NASDAQ:PYPD) - Defense World
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - The Manila Times
PolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100 - Nasdaq
PolyPid to Host Conference Call and Webcast to Discuss - GlobeNewswire
Major Clinical Trial Results: PolyPid's D-PLEX100 Shows New Data for Preventing Post-Surgery Infections - Stock Titan
Roth Capital Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - Nasdaq
Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rat - GuruFocus
Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rating | PYPD Stock News - GuruFocus
Roth Capital Initiates PolyPid at Buy With $9 Price Target - marketscreener.com
PolyPid initiated with a Buy at Roth Capital - TipRanks
What is HC Wainwright’s Forecast for PolyPid Q2 Earnings? - Defense World
FY2027 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Upgraded by HC Wainwright to “Buy” Rating - Defense World
PolyPid (NASDAQ:PYPD) Now Covered by HC Wainwright - Defense World
Wall Street Analyst Says PolyPid is a Buy with 300% Potential Upside as it nears Phase 3 Data Readout - newsblaze.com
PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Through Clinical Trials to Improve Surgical Outcomes, Enhance Treatment Efficacy, Minimize Side Effects - Yahoo Finance
H.C. Wainwright assumes coverage on PolyPid stock with buy rating - Investing.com
PolyPid assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright assumes coverage on PolyPid stock with buy rating By Investing.com - Investing.com India
PolyPid (PYPD) Receives a 'Buy' Rating from HC Wainwright & Co. - GuruFocus
H.C. Wainwright Initiates Buy Coverage on PolyPid (PYPD) with $1 - GuruFocus
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - Defense World
PolyPid Expands Share Option Plan to Boost Stakeholder Engagement - TipRanks
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid’s D-PLEX100 Approaches Critical Phase 3 Data Readout - Yahoo Finance
PolyPid at Lytham Partners: Strategic Advances and Financial Stability - Investing.com India
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call Transcript - MSN
PolyPid chairman to step down at June shareholder meeting By Investing.com - Investing.com Nigeria
PolyPid chairman to step down at June shareholder meeting - Investing.com Australia
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):